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Abstract
Background: Prevalence of HIV infection among people who inject drugs (PWID) has been reported to be higher
than that of the general population. The present study aimed to estimate the prevalence of HIV infection and
associated risk factors among PWID in Dar es Salaam, Tanzania, following the introduction of a comprehensive HIV
intervention package (CHIP) for PWID in the country in 2014.
Methods: We conducted an integrated bio-behavioral survey (IBBS) among PWID using respondent-driven
sampling (RDS) in Dar es Salaam, Tanzania, between October and December 2017. Data on socio-demographic
characteristics and risky behaviors were collected through face-to-face interviews. Blood samples were collected
and tested for HIV infection. We accounted for weighting in the analyses, and logistic regression was performed to
assess risk factors for HIV infection.
Results: A total of 611 PWID (94.4% males and 5.6% females) with a median age of 34 years (IQR 29–38) were
recruited. The overall prevalence of HIV infection was 8.7% (95% CI 6.5–10.9). The prevalence of HIV infections for
males and females were 6.8% (95% CI 4.7–8.9%) and 41.2% (95% CI 23.7–58.6%) respectively. Adjusted weighted
logistic regression analysis (WLRA) showed that being a female (aOR 19.1; 95% CI 5.9–61.8), injecting drugs for more
than 10 years (aOR = 7.32; 95% CI 2.1–25.5) compared to 1 year or less and being 45 years or older (aOR = 34.22;
95% CI 2.4–489.5) compared to being 25 years or younger were associated with increased odds of HIV infection.
Use of a sterile needle at last injection decreased odds of HIV infection (aOR = 0.3; 95% CI 0.1–0.8).
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Conclusions: The present study observed a decline in prevalence of HIV infections among PWID in Dar es Salaam
(8.7%) compared to a previous estimate of 15.5% from an IBBS conducted in 2013. Despite the decrease, HIV
prevalence remains high among PWID compared to the general population, and women are disproportionally
affected. The decline may be possibly attributed to the on-going implementation of CHIP for PWID, highlighting
the need for strengthening the existing harm reduction interventions by incorporating access to sterile needle/
syringe and addressing the layered risks for women.
Keywords: Prevalence, HIV, Risk factors, Injection drug use, IBBS, Tanzania
1. Background
Globally, it is estimated that there are 15.6 million
people who inject drugs (PWID), and 30% of these are
women [1]. In Tanzania, a national consensus size es-
timate from 2014 indicated the total number of people
who inject drugs (PWID) to be 30,000 individuals [2].
Injection drug use poses health problems in both low-
middle and high-income countries [3]. Among notable
complications of injection drug use is the transmission
of blood-borne infections, including HIV and viral
hepatitis [4]. PWID are at risk of drug overdoses, in-
cluding suicide related to drug use [5, 6]. In addition,
they can be affected by other mental health problems
[7]. Furthermore, injection drug use is also associated
with stigma, rejection, and incarceration [8, 9]. PWID
are disproportionally affected by HIV infection as com-
pared to the general population. The global average
prevalence of HIV infection among people who inject
drugs is 17.8% [1]. Several studies conducted in
Tanzania between 2010 and 2018 have reported that
the prevalence of HIV infection among PWID ranges
between 11.0 and 51.1% [2, 10–13]. These estimates
are 3 to 11 times higher than the prevalence of HIV
infection in the general population which is currently
4.5% [14]. In response to the high prevalence of HIV
infection observed among PWID, the Government of
Tanzania has rolled out a national comprehensive HIV
intervention package (CHIP) for PWID in 2014. CHIP
contains HIV intervention components such as bio-
medical interventions, social-behavioral interventions,
HIV diagnosis, treatment and care, and management
of co-infection and co-morbidities [15]. A total of six
medication-assisted treatment (MAT) clinics have been
established in mainland Tanzania along with several
other harm reduction interventions including a pilot
needle exchange program in one of the districts in
Dar es Salaam. Since the rollout of the CHIP among
key populations in Tanzania, no survey has been done
to investigate the prevalence of HIV infection and the
risk factors among PWID. The present study provides
data on the prevalence of HIV infection and associated
risk factors after the introduction of the CHIP in
Tanzania.
2. Methods
2.1. Study design and setting
A cross-sectional survey was carried out between Octo-
ber and December 2017 in Dar es Salaam, the largest
metropolitan city in Tanzania, with an estimated popula-
tion of 6.7 million in 2020 [16]. This study was part of a
broader integrated bio-behavioral survey that was con-
ducted among key populations in Dar es Salaam. The
city was chosen because of the high number of PWID
[2] and a high prevalence of HIV infection [11, 12].
2.2. Sample size calculation
Sample size estimates were based on the measurement
of precision of point estimates for the prevalence of HIV
infection among PWID. The sample size and power
calculation for this study was based on an estimated
prevalence of 16% from the IBBS which was conducted
in Dar es Salaam in 2014 [12]. The 95% confidence
interval and a 5% standard error were used to calculate
an appropriate sample size of 610 study participants.
2.3. Study population
The study participants were PWID aged 18 and above
residing in Dar es Salaam. Residency was defined as
having lived in the city for at least 12 months before the
survey. PWID were included in the study if they had
injected drugs in the past 3 months, presented with a
valid study coupon, and consented to participate in the
study.
2.4. Sampling procedures and recruitment
The study participants were recruited through
respondent-driven sampling (RDS). RDS is a recruitment
and sampling method that combines modified snowball
sampling with a mathematical model that weights the
sample to compensate for the fact that it was collected
in a non-random way [17]. Research assistants in con-
sultation with the study investigators purposefully
selected and recruited five seeds (i.e., the initial survey
participants). The selection was done so that the seeds
came from multiple locations to improve access to po-
tentially hidden networks of PWID. Subsequently, each
seed person recruited a maximum of three other
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participants by giving them recruitment coupons, and
this process continued so that the desired sample size
and the statistical power were reached. Participants were
screened for eligibility by a person who had injected
drugs in the past and recovered after therapy. The
screener used a standardized screening tool to ensure
objectivity. Interviews were done at a private, safe loca-
tion that was easily accessible to the participants. The
screener verified eligibility for all study participants by
looking for injection track marks and asking about
knowledge of local terms, injection practices, and drug
prices. The participants were only included in the study
if they possessed a valid recruitment coupon. Each cou-
pon was uniquely barcoded to link recruiters with
recruitees, and the barcode was also used to connect
participants with their consent forms, questionnaires as
well as HIV test results. A total of 8000 Tanzanian shil-
lings (3.50 USD) and 4000 Tanzanian shillings (1.75
USD) were paid to each participant for transport reim-
bursement and incentive for secondary recruitment, re-
spectively. The amounts used for primary and secondary
incentives were approved by the ethical review commit-
tee as the average travel costs to the study site.
2.5. Data collection training
A team of five research assistants with prior experience
in research was recruited and provided with a two-day
training on the study protocol, study instruments,
research ethics, HIV testing, as well as the procedures
for transportation and storage of biological samples. The
team was oriented on the use of an open data kit (ODK)
for data collection. ODK is a free and open-source data
collection software that was customized for our research
purpose. Additionally, the field team was trained on
interviewing skills and sensitivity in working with key
and vulnerable populations.
2.6. Data collection tool
A structured questionnaire was adapted from a previous
IBBS which was done in 2013 among PWID in Dar es Sa-
laam, Tanzania. The questionnaire was translated from
the English to Kiswahili and then back translated to Eng-
lish to ensure face validity (a simple form of validity based
on a subjective assessment). The version of the question-
naire used during the interviews was in Swahili, the
language spoken by the majority of Tanzanians. The ques-
tionnaire was pre-tested and also evaluated with a group
of PWID peer educators to ensure appropriate use of lan-
guage and alignment with cultural and peer norms. Using
handheld tablets, trained research assistants administered
the questionnaire and collected data using an ODK, which
were uploaded directly into the Muhimbili University of
Health and Allied Sciences (MUHAS) server daily. The
questionnaire gathered information on socio-demographic
characteristics, injection practices, sexual risk behaviors,
experience of violence, and alcohol use from the PWID
participants. Also, Blood samples were also taken and
tested for HIV infection.
3. Measures
3.1. Socio-demographic characteristics
Socio-demographic characteristics were gathered using a
questionnaire to describe the sample population. It in-
cluded age (continuous), gender (male or female), mari-
tal status (never married, married, separated/divorced/
widowed), average level of income per month (continu-
ous), employment status (none, self-employment,
employed, informal employment), and levels of educa-
tion (none, primary education, secondary education).
3.2. Injection practices and other risky behaviors for HIV
infection
Injection practices and other HIV risk behaviors were
measured as binary variables and included the following:
frequency of alcohol consumption in the past one
month, non-injection drug use other than alcohol in the
last 3 months, ever shared needles, having shared
needles in the past month, use of sterile needle at last
injection, ever used male condoms, experience of phys-
ical violence (beaten) in the past 12 months, and forced
to have sex in the past 12 months.
3.3. Biological data
Pre- and post-test counseling and HIV testing were per-
formed by a nurse and a laboratory technician at the
study site, and the national HIV testing algorithms were
followed. All specimens were screened using SD Bioline
HIV-1/2 3.0 test manufactured by Standard Diagnostics,
Inc., Korea [18, 19], and positive samples were con-
firmed using Determine HIV1/2 test manufactured by
Alere group of companies [20]. For discordant samples,
the tiebreaker test was Unigold HIV test manufactured
by Trinity Biotech, Ireland, and was used as a determin-
ing test [19].
3.4. Data management and statistical analysis
Data analysis was conducted using the RDS Analysis
Tool (RDSAT) and STATA version 15.1. To be able to
generate sample weight using RDSAT software package,
participants were asked for the number of PWID they
knew that they could recruit into the survey. They were
also asked for the number of PWID they have seen
during the last month, a number which was used in the
analysis of data when weighing the participant’s network
size. Per RDSAT data analysis procedures, data were
weighted by calculating weight as an inverse of the par-
ticipant’s network size and controlled for clustering by
multiplying the weight by the sample size and then
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dividing by the sum of the weight. Categorical variables
were summarized by calculating frequencies and per-
centages. The median and interquartile range were used
to summarize the age variable. The chi-square test was
used to compare differences in HIV infection by various
categorical variables. Weighted logistic regression ana-
lysis was used to estimate bivariate of the associations
between various risk factors and HIV infection. Only
covariates with a p value threshold of < 0.25 in the bi-
variate analyses were included in the logistic regression
model. Crude and adjusted odds ratios with 95% confi-
dence intervals were reported. All the analyses were
two-tailed, and a p value of less than 0.05 was consid-
ered statistically significant.
4. Results
4.1. Characteristic of study participants
The distribution of the socio-demographic characteris-
tics of the study participants is shown in Table 1. A total
of 611 PWID with a median age of 34 years (IQR 29–
38) were recruited through eight recruitment waves. The
majority of the study participants were males (94.4%).
About half of those who took part were unmarried
(52.9%), whereas 28.5% were divorced/separated or
widowed. Most of the participants were within the age
group 25–44 years (84.5%). About a third (30.4%) of the
participants reported a monthly income above 200,000
Tanzanian shillings (about 86 USD), whereas 20.3% re-
ported a monthly income of less than 50,000 shillings
(less than 22 USD). The largest proportion of the study
participants had completed primary school (67.6%). Al-
most three quarters (74.7%) of the study participants
reported being self-employed.
4.2. Risk factors for HIV infection
Table 2 shows the distribution of HIV risk factors. Al-
most one-third (29.0 %) of the study participants said
they had used needles previously used by others in the
Table 1 Descriptive characteristics of study participants (N = 611)
Characteristics Number of participants (n) Unweighted proportion (%) Weighted proportion (%)
Sex
Male 576 94.3 94.4
Female 35 5.7 5.6
Median age (IQR) 34 (29–38)
Age (years)
< 25 54 8.8 8.7
25–34 264 43.7 43.0
35–44 245 40.3 41.5
≥ 45 44 7.2 6.8
Completed educational level
None 113 21.8 23.5
Primary school 418 68.4 67.6
Secondary school 60 9.8 8.9
Income per month (Tshs)
< 50,000 116 19.0 20.3
50,000–120,000 145 23.7 25.7
120,000–200,000 95 15.6 17.6
> 200,000 255 41.7 30.4
Occupation
None 24 3.9 3.6
Self-employment 450 73.6 74.7
Employed 100 16.4 16.3
Informal employment 37 6.1 5.4
Marital status
Never married 323 52.9 52.7
Married 115 18.6 17.1
Separated/divorced/widowed 173 28.3 30.2
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past 1 month, while 41% reported ever have shared a
needle with someone else. About one-third (35.0%) of
the participants reported taking other non-injecting
drugs other than alcohol. Just above half of the partici-
pants had injected drugs for 7 years or more, while 44%
reported having injected drugs for more than 10 years.
About one-fifth of the participants (18%) reported that
they had not used a new sterile needle the last time they
injected. A majority of the participants (69%) reported
never having used alcohol. More than half of the partici-
pants (58%) had experienced both physical and sexual
violence, while about 14% had experienced sexual vio-
lence in the past year. Three-quarters of the participants
(75%) reported ever used a male condom.
4.3. Prevalence of HIV infection
The overall weighted prevalence of HIV infection was
8.7% (95% CI 6.4–11.8). Sex-disaggregated analysis







Used needle previous used by others in the past 1 month
Yes 173 28.3 29.0
No 438 71.7 71.0
Ever shared a needle with someone else
Yes 253 41.4 41.0
No 258 58.6 59.0
Taken any non-injected drugs other than alcohol in the last 3 months
Yes 202 33.1 35.0
No 409 66.9 65.0
Duration of injection drugs
< 1 year 47 7.7 9.0
1–3 years 108 17.7 17.0
4–6 years 117 19.1 29.0
7–9 years 76 12.4 12.0
10+ years 263 43.0 44.0
Used a new sterile needle last time injected
Yes 503 82.3 82.0
No 108 17.7 18.0
Ever used a male condom
Yes 455 74.5 75.0
No 156 25.5 25.0
Alcohol consumption
Never 413 67.7 69.0
2–3 times a week 31 5.1 4.9
more times a week 39 6.4 5.1
2–4 times a month 127 20.8 20.0
Experience of both form of violence
Yes 339 55.5 58
No 272 44.5 42
Experience of sexual violence
Yes 91 14.9 14
No 520 85.1 86
Experience of physical violence
Yes 226 37.0 35
No 385 63.0 65
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indicated that among males and females, the prevalence
of HIV infection was 6.8% (95% CI 4.7–8.9%) and 41.2%
(95% CI 23.7–58.6%). Among participants, who were
aged 45 and older, did not use a sterile needle at last
injection, and had injected drug for 10 years or more,
the prevalence of HIV was 22.4%, 16%, and 14.2%. Of all
the three risk factors, people injected for 10 years or
more have the least HIV prevalence.
4.4. Factors associated with HIV infection
Table 3 shows the results of bivariate and multivariate
regression analyses. We found that female gender, older
age, longer duration of injecting drug use, and using a
sterile needle during the last injection were independ-
ently associated with HIV infection among PWID.
Adjusted weighted analyses of risk factors for HIV infec-
tion indicated that being female (aOR = 19.1; 95% CI
5.9–61.8) was associated with increased odds of HIV in-
fection compared to males. We also found that being
aged 45 years or older (aOR = 34.2; 95% CI 2.4–489.5)
was associated with an increased odds of HIV infection
compared with those who were younger than 25 years.
Persons who had injected drugs for more than 10 years
had about seven times the odds of HIV infection as
compared to persons who had injected drugs for less
than a year (aOR = 7.3; 95% CI 2.1–25.5). However,
using a sterile needle during the last injection was inde-
pendently associated a 70% decreased odds of HIV infec-
tion (aOR = 0.3; 95% CI 0.1–0.8).
5. Discussion
With data from 611 PWID, we assessed the prevalence
of HIV and associated risk factors among PWID in Dar
es Salaam, Tanzania. We found that 8.7% of PWID res-
iding in Dar es Salaam, Tanzania, were infected with
HIV. This estimate is almost half of the prevalence re-
ported by a similar IBBS conducted in 2013 in the same
geographical area and by the same research team
(15.5%). In 2011, the results of a survey among PWID
attending outreach services in Dar e Salaam found HIV
prevalence to be 51.1%, almost six times higher than the
prevalence observed in the present study [11]. The
decrease in HIV prevalence among PWID suggested by
the findings of this study is in line with what has been
observed in the general Tanzanian population over the
past decade, during which the prevalence of HIV has de-
creased from 5.7% in 2008 to 4.7% in 2016 [14]. The
underlying reasons for the observed decline could be
multifactorial, e.g., mortality among HIV-infected PWID
or practice of safer injecting and sexual practices among
members of this population. It is also possible that the
observed decline has occurred as a consequence of safer
behaviors resulting from the rollout of the harm reduc-
tion services and comprehensive HIV interventions that
were implemented in the country in 2012 and 2014
respectively. The latter included MAT services and the
community-based and peer-led outreach services pro-
vided by several civil society organizations (CSOs) in the
vicinity.
Globally, the trends of the HIV epidemic among
PWID have not been well established. There are differ-
ent reports indicating both an increase and a decrease in
HIV infections in different parts of the world. Studies
have shown a reduction in HIV infection among people
who use drugs in some areas in the USA and Greece
[21, 22], while other studies have shown increases, such
as in Scotland [23]. Notable factors attributed to the
observed reduction of HIV infection among PWID in
Greece and Australia included the access to a combin-
ation of several prevention strategies such as
medication-assisted treatment, antiretroviral treatment
for HIV infection, and extensive needle/syringe exchange
programs [22, 24].
We found that there is a gender disparity in HIV
prevalence among PWID. Women had almost nineteen
times higher the odds of HIV infection compared to
men. As in the previous studies, we observed a higher
prevalence of HIV infection among WWID than among
their men counterparts [11, 12]. This gender disparity in
HIV infection may exist because women who inject
drugs have multiple layers of HIV infection risk. Women
who inject drugs may have additional risks related to
unsafe sexual practices, such as multiple concurrent sex-
ual partnerships, having an injection partner who is also
a sexual partner, and engaging in commercial sex to be
able to purchase drugs [25].
The duration of injecting drug use and the age of
PWID were found to be associated with HIV infection
in the present study. However, there is a potential collin-
earity between age of the PWID and the year spent
injecting drugs. This may mean that older PWID are
more likely to have spent many years injecting drugs
and make it possible that both variables measure the
same construct (i.e., duration of exposure to drug injec-
tion). Having injected drugs for more than 10 years and
being aged 45 years or older significantly increased the
odds of HIV infection. This finding is similar to other
studies among PWID [26]. The cumulative risk resulting
from older age and a long duration of exposure to HIV
risk behaviors may explain this association. Additionally,
the availability of HIV prevention and treatment services
for PWID which were established less than 10 years ago
could also partly explain these findings. This finding
may mean that before the rollout of harm reduction
services, PWID were more likely to engage in unsafe in-
jection practices and also other behaviors associated
with HIV risk that could explain the increased odds of
HIV infection among the older PWID and those who
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Bivariate analysis Multivariate analysis
cOR (95% CI) p value aOR (95% CI) p value
Sex**
Male 576 (94.4) 6.8 1 1
Female 35 (5.6) 42.0 14.7 (4.9–43.1) 0.000* 19.1(5.9–61.8) 0.000*
Age group (years)
< 25 54 (8.7) 2.9 1 1
25–34 264 (43.0) 5.8 2.1 (0.3–16.8) 0.498 5.4(0.4–76.4) 0200
35–44 245 (41.5) 10.8 4.0 (0.5–30.9) 0.180 11.6(0.9–144.5) 0.057
≥ 45 44 (6.8) 22.4 9.7 (1.1–86.9) 0.043* 34.2(2.4–489.5) 0.009*
Educational level
None 113 (23.5) 10.8 1
Primary education 418 (67.6) 7.4 0.7 (0.3–1.4) 0.273
Secondary education 60 (8.9) 13.4 1.3 (0.4–3.6) 0.648
Income per month (Tshs)
< 50,000 116 (20.3) 10.0 1 1
50,000–120,000 145 (25.7) 10.8 1.1 (0.4–2.8) 0.859 1.5 (0.5–4.5) 0.515
120,001–200,000 95 (17.6) 9.6 1.0 (0.4–2.6) 0.350 0.7 (0.2–2.3) 0.566
> 200,000 255 (30.4) 6.2 0.6 (0.3–1.4) 0.247 0.4 (0.2–1.9) 0.444
Occupation
None 24 (3.6) 6.0 1
Self employed 450 (74.7) 7.7 1.3 (0.2–11.0) 0.797
Employed 100 (16.3) 6.5 1.1 (0.1–10.1) 0.946
Informal employment 37 (5.4) 31.3 7.1 (0.8–63.1) 0.077
Marital status
Single 323 (52.7) 8.3 1
Married partner 115 (17.1) 8.0 1.0 (0.4–2.4) 0.928
Separated/Divorced 173 (30.2) 9.8 1.2 (0.56–2.6) 0.633
Ever shared needle
No 258 (41.0) 5.6 1 1
Yes 253 (59.0) 13.4 2.6 (1.3–5.1) 0.005* 2.2(0.8–6.3) 0.148
Used needle previous used by
others in the past 1 month
No 438 (71.0) 6.8 1 1
Yes 173 (29.0) 13.5 2.1 (1.08–4.24) 0.029* 0.7(0.2–2.0) 0.509
Taken any non-injected drugs other
than alcohol in the last three months
No 409 (65.0) 7.9 1
Yes 202 (35.0) 10.4 1.4 (0.7–2.7) 0.382
Duration injecting drugs (in years)
< 1 year 47 (9.0) 2.9 1 1
1–3 years 108 (17.0) 4.3 1.5 (0.2–8.8) 0.662 2.3 (0.5–10.9) 0.294
4–6 years 117 (29.0) 3.0 1.0 (0.1–7.4) 0.969 1.9 (0.3–10.0) 0.469
7–9 years 76 (12.0) 8.4 3.1 (0.5–17.3) 0.206 4.2 (0.9–19.0) 0.059
10+ years 263 (44.0) 14.2 5.5(1.2–25.8) 0.030* 7.3 (2.1–25.5) 0.002*
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used drugs for longer duration. Studies in Sub Saharan
Africa including from Tanzania have shown that the
coverage of harm reduction intervention is very low,
ranging from 20 to 40% [2]. By the end of 2015, only
2500 out of nearly 30,000 PWID were on MAT in
Tanzania [2]. It is imperative that the efforts to scale up
harm reduction interventions are increased to prevent
continued HIV risk exposure among PWID.
This study found that the use of clean syringes and
needles was independently associated with decreased
odds of HIV infection among PWID. These findings
concur with other studies that have found needled and
syringe programs (NSPs) to be effective in reducing HIV
infection [24, 27]. It is important to carefully evaluate
the current National Guideline for a Comprehensive
HIV Package for Key Population and strengthen the
NSPs as part of harm reduction for PWID in Tanzania.
6. Limitations
There are some limitations to this study. First, this is a
cross-sectional study which provides a snapshot of the
magnitude (prevalence) of HIV infection among PWID.
However, it does not allow for evaluation of the
temporal relationships between HIV infection and the
predictors of interest. Secondly, there is a possibility of
desirability bias due to the collection of sensitive infor-
mation related to injecting and sexual behaviors. Thirdly,
there is a potential for selection bias inherent in the
respondent-driven sampling which is a non-probabilistic
sampling approach. To mitigate this, seeds were selected
in such a way that they could represent the diversity of
PWID, including gender (male and female), various age
groups, and analysis, and took into account network size
and used special software (RDSAT) designed for this
kind of recruitment. Lastly, out of 611 participants, 35
were WWID constituting only 5.6% of the study sample.
Despite the fact that previous studies in the same city
have also reported fewer women who inject drugs and
higher HIV infection rates, the lower proportion of
women in this study may have biased gender compari-
son [12]. Difficulties in recruiting WWID in Tanzania
context can be explained by the idea that, WWID are
subjected to increased risk of physical violence (such as
assaults and robbery) as well as stigma and discrimin-
ation which in turn generate mistrust against health-
related activities and eventually push them in hiding and







Bivariate analysis Multivariate analysis
cOR (95% CI) p value aOR (95% CI) p value
Used a new sterile needle last time injected
No 108 (18) 16.4 1 1
Yes 503 (82) 7.1 0.4 (0.2–0.8) 0.005* 0.3 (0.1–0.8) 0.020*
Ever used a male condom
No 156 (25.0) 6.3 1 1
Yes 455 (75.0) 9.5 1.6(0.7–3.4) 0.246 1.7 (0.6–4.7) 0.277
Alcohol consumption
Never 413 (69.0) 8.0 1
2–3 times a week 31 (4.9) 7.5 0.9 (0.3–3.4) 0.914
4 or more times a week 39 (5.1) 10.9 1.4 (0.5–4.0) 0.515
2–4 times a month 127 (20.0) 11.1 1.4 (0.6–3.4) 0.400
Experience of both form of violence
No 272 (42) 6.5 1
Yes 339 (58) 11.8 1.9 (0.9–3.8) 0.064
Experience of physical violence
No 385 (65) 8.3 1
Yes 226 (35) 9.7 1.2 (0.6–2.3) 0.616
Experience of sexual violence
No 520 (86) 6.9 1 1
Yes 91 (14) 19.7 3.3 (1.6–6.7) 0.001* 1.2 (0.6–3.1) 0.718
Only covariates with a p value threshold of < 0.25 tin the bivariate analysis were included in the multivariate analysis
AOR adjusted odds ratio, cOR crude odds ratio, CI confidence interval
*A p value of 0.05 and below was considered statistically significant
**Unweighted Chi-square analysis was used to summarize of the percentage of HIV infection by sex
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being less accessible through the study’s RDS [28]. In
addition, some WWID are engaging in commercial sex
work which happens mostly during the night time and
hence make it difficult to be accessed during the day
time when RDS was taking place.
7. Conclusion
The results from this study suggest that the prevalence
of HIV among PWID in Dar es Salaam has decreased
considerably in the past 4 years. Despite the declining
trends of HIV infection for both the general population
and among PWID, the risk of being HIV positive for
PWID is almost twice that of people in the general
population. The decline in the prevalence of HIV could
be attributed to increased access to comprehensive HIV
interventions for key populations in Dar es Salaam,
which includes harm reduction intervention and access
to HIV testing, care, and treatment. The results may be
a sign of successful interventions that are helping to
realize the global targets of 90-90-90 and three zeros
[29]. Comprehensive HIV interventions should be rolled
out across the country, especially in the areas where
there is a substantial number of PWID.
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